Close Navigation
About Arix
Strategy
Overview
Investment Case
News
Results
Documents
Events
Calendar
Analysts
Stock info
Contact
About
Strategy
Team
Portfolio
Insights
Media
Contact
Investors
About
Strategy
Team
Portfolio
Insights
Media
Contact
Investors
Imara Announces Opening of Higher Dose Arms in Global Phase 2b Clinical Trials of IMR-687 for Sickle Cell Disease and Beta-Thalassemia
17th March 2021
Useful Tools
Download, print or share this article
Print Article
Email Article
Save Article
Share Article
Twitter
LinkedIn
Facebook